Medulloblastoma - Pipeline Insight, 2024

Medulloblastoma - Pipeline Insight, 2024

DelveInsight’s, “Medulloblastoma – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Medulloblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Medulloblastoma Understanding

Medulloblastoma: Overview

Medulloblastoma is a brain tumor of the cerebellum. The cerebellum controls balance and coordinated movements. The cerebellum is found near the brainstem in a region called the posterior fossa at the back of the brain. This fast-growing tumor can spread to other areas of the brain and spinal cord through cerebrospinal fluid (CSF). Symptoms of medulloblastoma depend on several things, including the tumor’s size and location, the child’s age, and stage of development. Symptoms may include: Headaches, Nausea and vomiting, Feeling tired or having changes in activity level, Clumsiness or loss of balance, Dizziness, Problems with handwriting, and Change in vision. Medulloblastoma is diagnosed based upon thorough clinical and neurological evaluation, detection of characteristic symptoms and physical findings, patient history, and specialized diagnostic tests. Primary CNS tumors are graded based on the tumor location, tumor type, extent of tumor spread, genetic findings, the patient’s age, and tumor remaining after surgery, if surgery is possible. Treatment includes surgery, radiation therapy (in patients >3 years old), or chemotherapy. The most effective treatment for medulloblastoma is a combination of therapies.

""Medulloblastoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medulloblastoma pipeline landscape is provided which includes the disease overview and Medulloblastoma treatment guidelines. The assessment part of the report embraces, in depth Medulloblastoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medulloblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Medulloblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Medulloblastoma.

Medulloblastoma Emerging Drugs Chapters

This segment of the Medulloblastoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Medulloblastoma Emerging Drugs

• 177Lu-omburtamab-DTPA: Y-mAbs Therapeutics

Omburtamab-Lu-177 is a theranostic humanized monoclonal antibody 8H9, conjugated to 177 lutetium. The drug is in Phase I/II clinical development for the treatment of medulloblastoma. 177Lu-omburtamab-DTPA embodies the Company’s naked omburtamab antibody radiolabeled with lutetium-177, using DTPA to chelate the lutetium radioisotope to the antibody. Omburtamab antibody was developed by researchers at Memorial Sloan Kettering (“MSK”), which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the compound and in Y-mAbs. The Committee for Orphan Medicinal Products (“COMP”) of the European Medicines Agency (“EMA”) has recommended the granting of orphan medicinal product designation (“OMPD”) in the European Union (“EU”) for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma.

• Silmitasertib (CX-4945): Senhwa Biosciences

Silmitasertib (CX-4945), an oral small molecule inhibitor of casein kinase 2 (CK2). It caused cell-cycle arrest and selectively induced apoptosis in cancer cells relative to normal cells. The drug is in Phase I/II clinical development for the treatment of Medulloblastoma. Silmitasertib is a first-in-class small molecule drug that targets Casein Kinase 2 (CK2), a protein involved in the DNA repair mechanism of cancer cells.

Further product details are provided in the report……..

Medulloblastoma: Therapeutic Assessment

This segment of the report provides insights about the different Medulloblastoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Medulloblastoma

There are approx. 15+ key companies which are developing the therapies for Medulloblastoma. The companies which have their Medulloblastoma drug candidates in the most advanced stage, i.e. Phase II include, Y-mAbs Therapeutics.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Medulloblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Medulloblastoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medulloblastoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medulloblastoma drugs.

Medulloblastoma Report Insights

• Medulloblastoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Medulloblastoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Medulloblastoma drugs?
• How many Medulloblastoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medulloblastoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Medulloblastoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Medulloblastoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Show more